Physical activity behaviors in cancer survivors treated with neurotoxic chemotherapy. Issue 1 (25th July 2022)

• Record Type: Journal Article
• Authors: Mizrahi, David; Goldstein, David; Trinh, Terry; Li, Tiffany; Timmins, Hannah C.; Harrison, Michelle; Marx, Gavin M.; Hovey, Elizabeth J.; Lewis, Craig R.; Friedlander, Michael; Park, Susanna B.
• Is Part Of: Asia-Pacific journal of clinical oncology. Volume 19:Issue 1(2023)
• Page Start: 243
• Page End: 249
• Publication Date: 2022-07-25
• Subjects: cancer -- chemotherapy -- exercise -- neurotoxicity -- peripheral neuropathy -- physical activity -- survivorship; Oncology -- Pacific Area -- Periodicals; Cancer -- Treatment -- Pacific Area -- Periodicals; Cancer -- Pacific Area -- Periodicals; Cancer -- Treatment -- Periodicals; 616.9940095
• DOI: 10.1111/ajco.13834
• Languages: English
• ISSNs: 1743-7555

Abstract

Abstract: Aim: There are many barriers to physical activity among cancer survivors. Survivors treated with neurotoxic chemotherapy may develop chemotherapy‐induced peripheral neuropathy (CIPN) and experience additional barriers related to sensorimotor and mobility deficits. This study examined physical activity behaviors, including physical activity predictors, among cancer survivors treated with neurotoxic chemotherapies. Methods: A cross‐sectional study of 252 participants, 3–24 months after neurotoxic chemotherapy, was undertaken. Physical activity was self‐reported (IPAQ). CIPN was self‐reported (FACT/GOG‐Ntx‐13), clinically graded (NCI‐CTCAE), and objectively measured using neurological grading scales and neurophysiological techniques (tibial and sural nerve conduction studies). Balance (Swaymeter) and fine motor skills (grooved pegboard) were assessed. Regression models were used to identify clinical, demographic and CIPN predictors of walking and moderate–vigorous physical activity. Results: Forty‐four percent of participants did not meet recommended physical activity guidelines (≥150 min/week). Sixty‐six percent presented with CIPN. Nineteen percent of participants with CIPN reported that symptoms interfered with their ability to be physically active. A lower proportion of survivors aged ≥60, with grade ≥1 CIPN or BMI ≥30, reported meeting physical activity guidelines (all p < .05). Regression models identified older age, higher BMI, and patient‐reported CIPN associated with lower walking, while higher BMI and females were associated with lower moderate–vigorous physical activity. Neurologically assessed CIPN did not associate with walking or moderate–vigorous physical activity. Conclusion: Cancer survivors exposed to neurotoxic chemotherapy have low physical activity levels. Further work should examine the factors causing physical activity limitations in this cohort and designing interventions to improve physical function and quality of life in survivors. Abstract : One in five participants with CIPN reported their symptoms interfered with their ability to exercise. Participants aged ≥60, with grade ≥1 CIPN or BMI ≥30, were less likely to meet physical activity guidelines. Tailored interventions are needed to increase physical activity post treatment to improve physical function and quality of life.